Pavella Therapeutics catalyst

Kaveri flags Pavella's pivotal Phase III data for a rare skin disease expected in March with potential 2027 approval.

Play episode from 16:13

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!